PolyPid Completes Key GMP Inspection for D-PLEX100 Manufacturing Readiness

The latest update is out from PolyPid ( (PYPD) ).

PolyPid Ltd. announced on September 16, 2025, the successful completion of a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health, marking its fourth consecutive successful inspection. This milestone confirms PolyPid’s readiness for commercial manufacturing of D-PLEX100, a key step towards its global commercialization following the positive Phase 3 SHIELD II trial results. The inspection aligns with European regulatory standards, reinforcing the company’s path to market entry in both the U.S. and European markets.

The most recent analyst rating on (PYPD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.

Spark’s Take on PYPD Stock

According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.

PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.

To see Spark’s full report on PYPD stock, click here.

More about PolyPid

PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through locally administered, controlled, prolonged-release therapeutics. The company’s proprietary PLEX technology enables precise drug delivery over extended periods. PolyPid’s lead product candidate, D-PLEX100, is aimed at preventing surgical site infections, with a New Drug Application submission expected in early 2026. The company also has a pipeline in oncology, obesity, and diabetes.

Average Trading Volume: 115,157

Technical Sentiment Signal: Sell

Current Market Cap: $34.55M

For a thorough assessment of PYPD stock, go to TipRanks’ Stock Analysis page.